Joint Replacement (Arthroplasty) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Joint replacement surgery (arthroplasty) is one of the most impactful surgical procedures in modern medicine, restoring pain-free function and mobility to patients disabled by end-stage joint disease. The procedure involves removing the damaged articular surfaces of a joint and replacing them with precisely engineered prosthetic components — typically composed of metal alloys (cobalt-chromium, titanium), medical-grade polyethylene, or ceramics — that recreate smooth, low-friction joint movement.

The scale of joint replacement surgery globally is enormous: more than 1 million total knee arthroplasties (TKA) and approximately 500,000 total hip arthroplasties (THA) are performed annually in the United States alone. The National Joint Registry (NJR) of England, Wales, and Northern Ireland holds data on over 3 million procedures performed since 2003 — the largest orthopaedic database in the world — and reports 10-year prosthesis survival rates of >95% for primary THA and >93% for primary TKA.

The decision to proceed with joint replacement follows a shared decision-making process between patient and surgeon, triggered by: (1) end-stage radiographic joint disease (Kellgren-Lawrence grade 3–4 osteoarthritis), (2) severe pain significantly impairing quality of life and daily activities, and (3) failure of at least 6 months of optimised conservative management (physiotherapy, NSAIDs, injections, weight loss).

Modern Enhanced Recovery After Surgery (ERAS) protocols have transformed the post-operative journey — hospital stay has shrunk from 5–7 days in the 1990s to 1–3 days as standard, with same-day discharge now feasible in carefully selected, medically optimised patients. Robotic-assisted surgery and computer navigation have further improved component positioning precision, reducing long-term revision risk.

Joint replacement is indicated for a range of end-stage joint pathologies:

• Osteoarthritis (OA): The primary indication, accounting for >95% of all elective joint replacements. Progressive cartilage destruction results in bone-on-bone contact, severe pain, and stiffness that does not respond to conservative measures. Knee, hip, and shoulder OA are the most frequent sites requiring replacement.
• Rheumatoid arthritis (RA): Despite dramatic improvements in biologic DMARD therapy preventing joint destruction, some RA patients develop end-stage joint failure requiring replacement. Bilateral, symmetric involvement is characteristic. Pre-operative anaesthetic assessment must include evaluation of cervical spine (atlantoaxial instability risk) and airway in long-standing RA.
• Osteonecrosis / avascular necrosis (AVN): Collapse of the femoral head (Ficat stage III–IV) or femoral condyle is a major indication for THA or TKA respectively; risk factors include glucocorticoid therapy, alcohol excess, sickle cell disease, diving, and hyperlipidaemia.
• Post-traumatic arthritis: Following intra-articular fractures of the distal femur, proximal tibia, acetabulum, or femoral head; often develops in younger patients, posing challenges for implant longevity.
• Displaced femoral neck fractures: Hemiarthroplasty (replacing the femoral head only, without acetabular component) is standard for displaced intracapsular hip fractures in older adults; total hip replacement offers superior functional outcomes in active, cognitively intact patients.
• Failed prior arthroplasty (revision surgery): Periprosthetic joint infection (PJI), aseptic loosening, instability, bearing surface wear, and periprosthetic fracture are indications for revision; revision surgery is significantly more complex and expensive than primary replacement.
• Tumour reconstruction: Following resection of primary bone tumours or extensive metastatic disease, megaprostheses (custom or modular) replace large bony segments.

Patient selection for joint replacement balances surgical risk against expected functional benefit. There is no absolute age threshold — physiological fitness rather than chronological age drives candidacy. Key criteria include:

• Radiographic end-stage disease: Kellgren-Lawrence grade 3–4 OA (joint space narrowing, osteophytes, subchondral sclerosis/cyst) on weight-bearing X-ray; Ficat stage III–IV for AVN; established articular destruction on CT/MRI if plain X-rays are equivocal.
• Severity of functional impairment: Standardised outcome scores guide eligibility — Oxford Knee Score (OKS <26 out of 48 indicating severe OA); Oxford Hip Score; HOOS/KOOS; NRS pain ≥7 at rest or on movement. The NHS England Commissioning Guidance uses the OKS plus patient-reported impact to guide referral thresholds.
• Failure of conservative management: Minimum 6 months of structured physiotherapy, weight management, appropriate analgesics (oral NSAIDs, topical agents), and at least one intra-articular injection trial before surgical referral in elective OA cases.
• Medical optimisation: BMI <40 is the recommended threshold for elective surgery (BMI >50 associated with 3-fold increase in surgical complication rate); smoking cessation at least 6 weeks pre-operatively (reduces wound and anaesthetic complications); pre-operative anaemia correction — target haemoglobin >120 g/L (iron supplementation, EPO if required); HbA1c <69 mmol/mol (8.5%) in diabetics; cardiorespiratory optimisation for ASA III+ patients.
• Contraindications: Active infection at or near the joint (absolute); neurological conditions causing severe muscle weakness (relative — risk of instability); severe dementia affecting rehabilitation compliance; life expectancy <1 year; patient preference (some patients accept significant disability rather than surgical risk).

Joint replacement options are tailored to the joint affected, the extent of disease, and patient characteristics:

Total Knee Arthroplasty (TKA): Resurfacing of the distal femur, proximal tibia, and patellar (optional) with metal and polyethylene components. Implant designs:

• Cruciate-retaining (CR): Preserves the posterior cruciate ligament (PCL); requires intact PCL.
• Posterior-stabilised (PS): PCL is resected; a polyethylene post-and-cam mechanism provides AP stability; more reproducible kinematics in PCL-deficient or deformed knees.
• Unicompartmental knee arthroplasty (UKA): Resurfacing of one compartment only (medial or lateral); preserves cruciate ligaments and unaffected compartments; faster recovery, more natural kinematics; strict patient selection (isolated compartment disease, BMI <30, flexion >90°, varus/valgus deformity <15°); revision rates slightly higher than TKA at 10 years in registry data.
• Robotic-assisted TKA (MAKO, Stryker; ROSA, Zimmer Biomet): Provides intraoperative CT-guided haptic control of the cutting tool; achieves component alignment within ±1° of plan in multiple studies; reduces outliers in coronal and sagittal alignment; cost premium $2,000–$5,000; long-term survivorship benefit still being established in registries.

Total Hip Arthroplasty (THA):

• Surgical approach: Posterior (most common — excellent visibility, risk of posterior dislocation ~1–3%); direct anterior (muscle-sparing, lower dislocation risk, steeper learning curve); anterolateral/Hardinge (intermediate); dual-mobility cup addresses dislocation risk in high-risk patients.
• Bearing surfaces: Ceramic-on-polyethylene (most common; low wear, excellent durability); ceramic-on-ceramic (lowest wear rate; squeaking in ~1%); metal-on-polyethylene (established but higher wear than ceramic); metal-on-metal — largely abandoned due to metal ion toxicity and adverse local tissue reactions (ALTR/ALVAL).
• Hemiarthroplasty: Austin Moore (uncemented) or Thompson (cemented) — femoral head only replaced, no acetabular resurfacing; indicated for elderly, low-demand patients with femoral neck fracture.

Shoulder Arthroplasty:

• Anatomic TSA (total shoulder arthroplasty): Humeral head + glenoid surface replacement; indicated for OA with intact rotator cuff; excellent pain relief and ROM restoration.
• Reverse TSA (RTSA): Reverses the ball-and-socket geometry — glenosphere placed on the glenoid, socket on the humerus; deltoid muscle (rather than rotator cuff) drives the prosthesis; standard of care for cuff tear arthropathy, irreparable rotator cuff tears with OA, and complex fracture sequelae in elderly patients; dramatically expanded indication now includes primary OA in older patients.

Ankle Arthroplasty: Total ankle replacement (e.g., STAR, Salto Talaris, INFINITY) preserves motion compared with arthrodesis (fusion); 10-year survivorship ~85–90% in specialist centres; indicated for end-stage ankle OA in patients without severe malalignment.

Blood management — Tranexamic acid (TXA): IV and/or topical TXA is now standard care; the TRANX trial and meta-analyses demonstrate ~50% reduction in blood transfusion requirement; bilateral TKA without TXA previously carried ~30% transfusion rate, now reduced to <5% with TXA.

Joint replacement is consistently among the most cost-effective and patient-satisfying surgical procedures performed:

• Dramatic pain relief: Over 90% of patients report good or excellent pain relief at 5 years post primary TKA and THA; mean NRS pain scores typically fall from 7–8 pre-operatively to 1–2 post-operatively. Patient Reported Outcome Measures (PROMs — OKS, OHS, EQ-5D) show large magnitude improvements exceeding the minimum clinically important difference (MCID) in >85% of patients.
• Functional restoration: THA patients typically resume walking without a limp at 6–8 weeks; TKA patients walk unaided by 3–4 weeks; stair climbing, car transfer, and community walking are restored in the majority by 6–8 weeks. Return to low-impact recreational sport (cycling, swimming, golf, doubles tennis) is feasible at 6–12 months.
• Implant longevity: National joint registries report THA prosthesis survival rates of ~95% at 10 years and ~85–90% at 20 years for primary procedures. TKA 10-year survival is ~93–95%. Modern highly-crosslinked polyethylene bearings have dramatically reduced wear-related revision rates compared with conventional polyethylene used before 2000.
• Quality of life and cost-effectiveness: Joint replacement is cost-effective at <$50,000 per QALY (quality-adjusted life year) gained — comparable to cardiac stenting and breast cancer treatment, and significantly below the commonly cited $100,000 QALY threshold. Health economic modelling shows THA and TKA both generate >5 QALYs per procedure when performed at the right time.
• Cardiovascular risk reduction: Reduced mobility from OA is associated with physical inactivity, obesity, and cardiovascular disease. Restoration of mobility post-arthroplasty is associated with increased physical activity levels and modest cardiovascular risk reduction in population-level analyses.

Joint replacement carries well-characterised risks that vary by procedure, patient factors, and surgical volume. Patients must be counselled comprehensively before consenting:

• Periprosthetic joint infection (PJI): The most feared complication — incidence 0.5–2% for primary procedures (higher for revision, diabetics, obesity, immunosuppression). PJI typically requires 2-stage revision surgery (implant removal, antibiotic spacer, reimplantation 6–12 weeks later) with prolonged IV and oral antibiotics; mortality risk associated with PJI is ~2–5%. Prevention: pre-operative skin decolonisation (nasal mupirocin + chlorhexidine wash), prophylactic IV antibiotics (cefazolin) at induction, laminar flow theatres, orthopaedic impervious draping.
• Aseptic loosening: The leading cause of long-term revision; occurs due to wear particle-induced bone loss (osteolysis) or biological failure of bone-implant integration; annual revision rate ~0.3–0.5% for primary TKA/THA; cemented fixation slightly more durable in elderly patients; cementless fixation preferred in younger patients for ease of revision.
• Venous thromboembolism (DVT/PE): Major orthopaedic surgery carries high VTE risk; with pharmacological prophylaxis (LMWH such as enoxaparin, or aspirin — ASPIRE and PULSAR trials) + mechanical prophylaxis (TED stockings, intermittent pneumatic compression), symptomatic DVT rate <1% and fatal PE <0.1%; prophylaxis continued for 10–14 days (TKA) or 28–35 days (THA).
• Instability and dislocation: Posterior THA — dislocation rate ~1–3%; greatest risk in the first 3 months post-operatively; risk reduced by dual-mobility cups; TKA instability — related to PCL sacrifice or MCL deficiency, managed with PS or constrained implants.
• Periprosthetic fracture: Intraoperative or post-operative fracture around the implant stem or tibial tray; requires ORIF or revision surgery; incidence ~0.5–2.5% over 20-year follow-up.
• Nerve injury: Peroneal nerve palsy ~0.5–1% after THA (especially after correction of severe fixed flexion); femoral nerve neurapraxia after anterior approach THA (<1%); majority resolve within 6–12 months.
• Stiffness (TKA): Flexion <90° at 3 months occurs in ~10% of TKA patients; manipulation under anaesthesia (MUA) at 6–12 weeks post-op is effective if stiffness persists; risk factors include pre-operative stiffness, obesity, and inadequate physiotherapy.
• Residual pain (TKA): Approximately 15–20% of TKA patients report persistent knee pain or dissatisfaction at 1 year (CROP study, UK); causes include component malalignment, patellofemoral complications, ongoing neuropathic pain, or unrealistic expectations. This rate is lower for THA (~7–10% dissatisfaction).

Enhanced Recovery After Surgery (ERAS) protocols for joint replacement represent the evidence-based standard of care, combining multiple perioperative optimisation strategies:

Pre-operative ERAS elements:

• Pre-operative education programme (joint school) — evidence-based counselling on procedure, recovery timeline, physiotherapy exercises, home adaptations, and expected milestones.
• Carbohydrate loading: clear carbohydrate drinks up to 2 hours before anaesthesia (contra to traditional 6-hour fasting); reduces insulin resistance and post-operative nausea.
• Pre-operative analgesia: paracetamol 1g + celecoxib 200 mg + gabapentin 300 mg administered orally 1–2 hours pre-operatively (multimodal pre-emptive analgesia).

Intraoperative ERAS elements:

• Anaesthesia: spinal anaesthesia (subarachnoid block) preferred over general anaesthesia — associated with faster recovery, less nausea, lower blood loss, shorter hospital stay.
• Local infiltration analgesia (LIA): periarticular injection of ropivacaine + ketorolac + adrenaline provides 24–48 hours of local pain control.
• Tranexamic acid: IV 1g at induction + 1g at skin closure OR topical 3g in the wound cavity; reduces transfusion rate ~50%.
• Tourniquet: Used selectively; bloodless field during cementation; released before wound closure; reducing total tourniquet time (<60 minutes) minimises post-operative pain and swelling.

Post-operative ERAS elements:

• Early mobilisation: Patient sits out of bed and walks (with physiotherapist) on the day of surgery (Day 0) — the single most impactful ERAS element; reduces DVT risk, deconditioning, and length of stay.
• Multimodal analgesia: Scheduled paracetamol + NSAID (ketorolac → celecoxib) + opioid PRN; opioid-sparing targets to avoid ileus and sedation.
• DVT prophylaxis: LMWH (enoxaparin 40 mg daily) started 6–12 hours post-operatively for 14 days (TKA) or 28–35 days (THA); or aspirin 150 mg daily (ASPIRE trial — non-inferior for THA/TKA).
• Hospital discharge: Day 1–3 with adequate pain control, independent mobilisation on stairs, wound integrity, and home support confirmed.
• Post-discharge rehabilitation: Outpatient physiotherapy 6–12 weeks; clinical review at 6 weeks, 3 months, and 12 months; radiograph at 6 weeks and 12 months for component assessment.
• Long-term follow-up: 5-yearly clinical and radiographic review until implant failure or patient death; national joint registry enrolment (UK NJR, Australian AOANJRR) enables long-term implant surveillance.

Joint replacement costs vary dramatically by country, setting, implant selection, and whether primary or revision surgery is required:

• United States: Primary TKA: $25,000–$45,000 (hospital + surgeon + anaesthesia); primary THA: $28,000–$50,000; robotic-assisted add-on: $2,000–$5,000; bilateral simultaneous TKA: 20–30% more than unilateral. Insurance coverage: Medicare (Part A hospital, Part B physician) covers joint replacement for medically eligible patients aged 65+; commercial insurers cover primary replacement for covered indications; significant cost-sharing (deductibles, co-insurance) applies.
• United Kingdom (NHS): NHS joint replacement is free at point of care for eligible patients; waiting times vary by region (4–18 months for elective OA); private sector: £10,000–£18,000 for primary TKA; £12,000–£22,000 for primary THA.
• India: Primary TKA: ₹2,50,000–₹6,00,000 ($3,000–$7,500 USD) at accredited private hospitals (Fortis, Apollo, Manipal, AIIMS); primary THA: ₹2,00,000–₹5,00,000 ($2,500–$6,500 USD); import-quality implants add ₹50,000–₹1,50,000. India is a leading medical tourism destination for joint replacement, attracting patients from Africa, the Middle East, and South-East Asia.
• Thailand: TKA: $10,000–$18,000 USD at JCI-accredited hospitals (Bumrungrad, Bangkok Hospital); THA: $10,000–$16,000; implant quality equivalent to international standard.
• Malaysia: TKA: $8,000–$14,000 USD (Prince Court Medical Centre, Pantai, KPJ hospitals); among the lowest cost for high-quality joint replacement globally.
• Implant cost factors: Standard cruciate-retaining TKA implant (US): $3,000–$5,000; premium ceramic bearing THA: $4,000–$7,000; revision implants: $8,000–$20,000; custom megaprostheses: $20,000–$80,000.
• Revision vs primary: Revision arthroplasty typically costs 2–3× more than primary, requires specialised implants (augments, stems, cones), has a higher complication rate, and achieves lower patient satisfaction than primary.

Several surgical and non-surgical alternatives may be considered, particularly for younger patients or those where arthroplasty carries unacceptable risk:

• Optimised conservative management: Structured physiotherapy (particularly quadriceps and hip abductor strengthening for knee OA), weight management, NSAIDs, intra-articular injections (corticosteroid, viscosupplementation, PRP), and lifestyle modification should be exhausted before surgery is considered. Some patients with KL grade 3–4 OA achieve adequate symptom control without surgery.
• Unloader bracing: Valgus unloader knee brace for medial compartment OA — offloads the affected compartment, reduces pain and NSAID consumption; most effective in patients with moderate-severity OA, varus deformity <15°, and BMI <35; not a permanent solution but may delay surgery by 1–5 years.
• High tibial osteotomy (HTO): For varus knee OA in active patients under 60 with isolated medial compartment disease and preserved lateral cartilage; a closing or opening wedge osteotomy of the proximal tibia shifts body weight to the less damaged lateral compartment; 10-year survivorship avoiding arthroplasty ~70–80% in appropriate candidates; does not preclude subsequent TKA.
• Unicompartmental knee arthroplasty (UKA): For isolated medial or lateral compartment OA in appropriate candidates — preserves cruciate ligaments and bone stock; faster recovery than TKA; national registry 10-year revision rate ~15–20% (higher than TKA); conversion to TKA when required is straightforward.
• Joint regeneration procedures: Microfracture, MACI, osteochondral grafting — for focal chondral defects in younger patients with otherwise preserved joint; not appropriate for diffuse OA. See Joint Regeneration guide.
• Arthrodesis (joint fusion): Ankle fusion is still performed as an alternative to total ankle replacement in younger, high-demand patients or those with severe deformity; provides reliable pain relief at the cost of eliminated motion; hip fusion (now rarely performed) and shoulder fusion (rare — for failed arthroplasty).
• Pharmacological disease modification (RA): Modern biologic and targeted synthetic DMARDs effectively prevent structural progression and end-stage joint damage in the majority of RA patients — reducing the long-term need for joint replacement.